| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Peter A Calabresi | |
| Daniel M Harrison | |||
| P2860 | cites work | Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis | Q24647406 |
| Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy | Q24683776 | ||
| Potassium channels as therapeutic targets for autoimmune disorders | Q28212654 | ||
| High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis | Q28257661 | ||
| B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
| Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group | Q28293763 | ||
| LINGO-1 negatively regulates myelination by oligodendrocytes | Q28588853 | ||
| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis | Q29616119 | ||
| Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 | Q29619644 | ||
| Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed | Q30982510 | ||
| Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. | Q33319975 | ||
| Alemtuzumab vs. interferon beta-1a in early multiple sclerosis | Q33381736 | ||
| Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials | Q33898885 | ||
| Advances in interleukin 2 receptor targeted treatment | Q34071328 | ||
| Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) | Q34375520 | ||
| Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. | Q34405210 | ||
| Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study | Q34515400 | ||
| Oral fingolimod (FTY720) for relapsing multiple sclerosis | Q34565985 | ||
| Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results | Q34665233 | ||
| Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. | Q34788240 | ||
| Cladribine (2-chlorodeoxyadenosine) | Q35267370 | ||
| New targets for treatment of multiple sclerosis | Q37259755 | ||
| Axonal protective effects of the myelin-associated glycoprotein | Q37413837 | ||
| Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results | Q38395229 | ||
| Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. | Q40637757 | ||
| The immune modulator FTY720 targets sphingosine 1-phosphate receptors | Q40736684 | ||
| Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma | Q41505579 | ||
| The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. | Q41649755 | ||
| Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. | Q42802801 | ||
| Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. | Q43668453 | ||
| Suppression of experimental autoimmune neuritis by leflunomide | Q43719857 | ||
| Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue | Q43977414 | ||
| Cladribine in treatment of chronic progressive multiple sclerosis | Q44496335 | ||
| Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats | Q45090895 | ||
| Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial | Q45119459 | ||
| Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab | Q45857012 | ||
| Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. | Q46078718 | ||
| Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study | Q46175975 | ||
| Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study | Q46276281 | ||
| FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. | Q46318655 | ||
| Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial | Q46353641 | ||
| Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis | Q48087197 | ||
| A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses | Q48602930 | ||
| CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. | Q48923891 | ||
| The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. | Q50766232 | ||
| Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. | Q51971434 | ||
| Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. | Q51987968 | ||
| Daclizumab in treatment of multiple sclerosis patients | Q57083584 | ||
| PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AFTER RITUXIMAB IN A CASE OF NON-HODGKIN LYMPHOMA | Q57254142 | ||
| Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial | Q57911989 | ||
| Assault on the guardian | Q60096440 | ||
| Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis | Q61415557 | ||
| Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes | Q63641262 | ||
| Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group | Q70650973 | ||
| Marrow suppression produced by repeated doses of cladribine | Q72394880 | ||
| Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group | Q74038855 | ||
| A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis | Q77807709 | ||
| Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab | Q80112082 | ||
| Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study | Q80419633 | ||
| Anti-glomerular basement membrane disease after alemtuzumab | Q81784549 | ||
| LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence | Q94706491 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 283-290 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | Annals of Indian Academy of Neurology | Q4767851 |
| P1476 | title | Promising treatments of tomorrow for multiple sclerosis | |
| P478 | volume | 12 |
Search more.